Report: Small European biotechs suffer from lack of funds

04/14/2005 | Wall Street Journal, The

A report from Critical I found the European biotech industry is being held back by a financial structure unable to help firms move treatments into late-stage research. Because smaller biotechs are unable to secure sufficient funding, many companies close after three to four years. An official with EuropaBio says, "it is crucial the European Union reconsiders how it should stimulate the market to invest in innovation."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY